Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer
0
Sign in to get full access
Overview
- Explores the use of network medicine and generative AI (GenAI) to accelerate drug repurposing for complex diseases, using breast cancer as a case study.
- Highlights the challenges of treating complex diseases and the potential of network-based approaches and GenAI to address these challenges.
- Demonstrates a framework that integrates network analysis, drug-target interactions, and GenAI to identify promising drug candidates for breast cancer.
Plain English Explanation
Complex diseases like cancer are difficult to treat because they involve intricate networks of interacting factors, from genetics to environmental influences. Traditional drug development approaches can be slow and expensive, often failing to address the underlying complexity of these diseases.
This research paper explores how the emerging fields of network medicine and generative AI (GenAI) can be used to accelerate the drug repurposing process for complex diseases, using breast cancer as an example. Drug repurposing is the practice of finding new uses for existing drugs, which can be faster and more cost-effective than developing completely new drugs.
The researchers developed a framework that combines network analysis, drug-target interactions, and GenAI to identify promising drug candidates for breast cancer. By modeling the complex web of biological interactions involved in the disease, they were able to pinpoint existing drugs that could potentially be repurposed to treat breast cancer more effectively.
The use of GenAI, such as large language models (LLMs), allowed the researchers to generate and evaluate a vast number of potential drug candidates, accelerating the discovery process. This approach holds promise for addressing the challenges of complex diseases and improving treatment options for patients.
Technical Explanation
The researchers first constructed a multilayered network model that integrated various data sources, including gene expression, protein-protein interactions, and drug-target relationships. This network model captured the complex interconnections between biological entities and provided a holistic view of the disease landscape.
Next, the researchers employed network-based algorithms to identify key genes, proteins, and pathways involved in breast cancer. By analyzing the network topology and dynamics, they were able to uncover important disease-related modules and potential drug targets.
To accelerate the drug repurposing process, the researchers leveraged the power of GenAI, specifically LLMs. These models were trained on vast amounts of biomedical data and were able to generate and evaluate a large number of potential drug candidates, exploring a much broader chemical space than traditional methods.
The framework proposed in this paper combines the strengths of network medicine and GenAI to facilitate the identification of promising drug repurposing opportunities for breast cancer. The researchers demonstrated the effectiveness of this approach through case studies and showed how it can be extended to other complex diseases.
Critical Analysis
The paper presents a compelling and innovative framework that integrates network medicine and GenAI for drug repurposing in complex diseases. The authors have addressed several key challenges in this domain, including the inherent complexity of biological systems and the limitations of traditional drug discovery methods.
One potential limitation of the study is the reliance on existing data sources, which may not capture the full complexity of the disease landscape. The authors acknowledge this and suggest that the framework could be further enhanced by incorporating additional data types and incorporating real-world clinical evidence.
Additionally, while the use of GenAI is a promising approach, the paper does not provide a detailed evaluation of the specific LLM architectures and training data used. Further research could explore the impact of different GenAI models and training strategies on the drug repurposing process.
Overall, this research represents a significant step forward in leveraging network medicine and GenAI to accelerate the development of new treatments for complex diseases. The findings presented in this paper have important implications for the field of drug repurposing and could lead to more effective and efficient therapies for patients with diseases like breast cancer.
Conclusion
This paper demonstrates the potential of combining network medicine and generative AI (GenAI) to accelerate the drug repurposing process for complex diseases, using breast cancer as a case study. By integrating various biological data sources into a multilayered network model and leveraging the power of LLMs, the researchers were able to identify promising drug candidates that could be repurposed to treat breast cancer more effectively.
The framework proposed in this paper represents a significant advancement in the field of complex disease research and treatment. By harnessing the strengths of network-based approaches and the latest advancements in AI, this work could lead to the development of more effective and personalized therapies for patients with complex diseases. As the field of network medicine and GenAI continues to evolve, this research serves as a valuable example of how these technologies can be applied to accelerate the drug discovery and repurposing process.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
Accelerating Complex Disease Treatment through Network Medicine and GenAI: A Case Study on Drug Repurposing for Breast Cancer
Ahmed Abdeen Hamed, Tamer E. Fandy
The objective of this research is to introduce a network specialized in predicting drugs that can be repurposed by investigating real-world evidence sources, such as clinical trials and biomedical literature. Specifically, it aims to generate drug combination therapies for complex diseases (e.g., cancer, Alzheimer's). We present a multilayered network medicine approach, empowered by a highly configured ChatGPT prompt engineering system, which is constructed on the fly to extract drug mentions in clinical trials. Additionally, we introduce a novel algorithm that connects real-world evidence with disease-specific signaling pathways (e.g., KEGG database). This sheds light on the repurposability of drugs if they are found to bind with one or more protein constituents of a signaling pathway. To demonstrate, we instantiated the framework for breast cancer and found that, out of 46 breast cancer signaling pathways, the framework identified 38 pathways that were covered by at least two drugs. This evidence signals the potential for combining those drugs. Specifically, the most covered signaling pathway, ID hsa:2064, was covered by 108 drugs, some of which can be combined. Conversely, the signaling pathway ID hsa:1499 was covered by only two drugs, indicating a significant gap for further research. Our network medicine framework, empowered by GenAI, shows promise in identifying drug combinations with a high degree of specificity, knowing the exact signaling pathways and proteins that serve as targets. It is noteworthy that ChatGPT successfully accelerated the process of identifying drug mentions in clinical trials, though further investigations are required to determine the relationships among the drug mentions.
Read more6/28/2024
0
DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning
Yoshitaka Inoue, Tianci Song, Tianfan Fu
Drug repurposing offers a promising avenue for accelerating drug development by identifying new therapeutic potentials of existing drugs. In this paper, we propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb), DrugBank, Comparative Toxicogenomics Database (CTD), and Search Tool for Interactions of Chemicals (STITCH) to systematically extract DTIs; and a Search Agent interacts with biomedical literature to annotate and verify computational predictions. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates. Preliminary results demonstrate the potential of our approach in not only predicting drug-disease interactions but also in reducing the time and cost associated with traditional drug discovery methods. This paper highlights the scalability of multi-agent systems in biomedical research and their role in driving innovation in drug repurposing. Our approach not only outperforms existing methods in predicting drug repurposing potential but also provides interpretable results, paving the way for more efficient and cost-effective drug discovery processes.
Read more9/18/2024
🗣️
0
Learning a Patent-Informed Biomedical Knowledge Graph Reveals Technological Potential of Drug Repositioning Candidates
Yongseung Jegal, Jaewoong Choi, Jiho Lee, Ki-Su Park, Seyoung Lee, Janghyeok Yoon
Drug repositioning-a promising strategy for discovering new therapeutic uses for existing drugs-has been increasingly explored in the computational science literature using biomedical databases. However, the technological potential of drug repositioning candidates has often been overlooked. This study presents a novel protocol to comprehensively analyse various sources such as pharmaceutical patents and biomedical databases, and identify drug repositioning candidates with both technological potential and scientific evidence. To this end, first, we constructed a scientific biomedical knowledge graph (s-BKG) comprising relationships between drugs, diseases, and genes derived from biomedical databases. Our protocol involves identifying drugs that exhibit limited association with the target disease but are closely located in the s-BKG, as potential drug candidates. We constructed a patent-informed biomedical knowledge graph (p-BKG) by adding pharmaceutical patent information. Finally, we developed a graph embedding protocol to ascertain the structure of the p-BKG, thereby calculating the relevance scores of those candidates with target disease-related patents to evaluate their technological potential. Our case study on Alzheimer's disease demonstrates its efficacy and feasibility, while the quantitative outcomes and systematic methods are expected to bridge the gap between computational discoveries and successful market applications in drug repositioning research.
Read more7/25/2024
0
A deep graph model for the signed interaction prediction in biological network
Shuyi Jin, Mengji Zhang, Meijie Wang, Lun Yu
In pharmaceutical research, the strategy of drug repurposing accelerates the development of new therapies while reducing R&D costs. Network pharmacology lays the theoretical groundwork for identifying new drug indications, and deep graph models have become essential for their precision in mapping complex biological networks. Our study introduces an advanced graph model that utilizes graph convolutional networks and tensor decomposition to effectively predict signed chemical-gene interactions. This model demonstrates superior predictive performance, especially in handling the polar relations in biological networks. Our research opens new avenues for drug discovery and repurposing, especially in understanding the mechanism of actions of drugs.
Read more7/11/2024